Literature DB >> 26953213

Use of Antipsychotics for the Treatment of Behavioral Symptoms of Dementia.

H Karl Greenblatt1, David J Greenblatt1.   

Abstract

Antipsychotic medications are widely used in the management of behavioral and psychological symptoms of dementia. While nonpharmacological interventions should be the first-line treatment for behavioral symptoms of dementia, these are often unfeasible and/or ineffective. Conventional and atypical antipsychotic agents appear to have modest to moderate clinical efficacy in the treatment of these symptoms, though it is unclear which individual agents are most effective. No conclusive evidence exists that any available alternative medications are safer and more effective than antipsychotics. A number of studies have shown an increased risk of mortality associated with antipsychotics in patients with behavioral symptoms of dementia, though the observed risk increase may be partially confounded by illness severity and/or preexisting health determinants. The mechanisms of increased mortality risk are not fully established, but are likely to involve cardiovascular events. It is probable, though not certain, that conventional antipsychotics are associated with a greater number of poor outcomes than atypical antipsychotics. In certain patients with refractory behavioral symptoms, antipsychotics are a viable treatment option. Key considerations for antipsychotic prescribing for this population are published in regulatory guidelines, and include minimization of dosage and duration of treatment, continuous reevaluation of symptoms, and involvement of caregivers.
© 2016, The American College of Clinical Pharmacology.

Entities:  

Keywords:  antipsychotics; behavioral symptoms; dementia; nursing homes

Mesh:

Substances:

Year:  2016        PMID: 26953213     DOI: 10.1002/jcph.731

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  9 in total

Review 1.  Interventions to Improve Medicines Management for People with Dementia: A Systematic Review.

Authors:  Mairead McGrattan; Cristín Ryan; Heather E Barry; Carmel M Hughes
Journal:  Drugs Aging       Date:  2017-12       Impact factor: 3.923

Review 2.  Evidence and decision algorithm for the withdrawal of antipsychotic treatment in the elderly with dementia and neuropsychiatric symptoms.

Authors:  Marta Miarons; Christopher Cabib; Francisco Javier Barón; Laia Rofes
Journal:  Eur J Clin Pharmacol       Date:  2017-08-05       Impact factor: 2.953

3.  Off-label use of quetiapine in nursing homes: Does medical specialty of prescribing physicians play a role?

Authors:  Laura Müller; Roberta Noseda; Raffaela Bertoli; Marco Bissig; Alessandro Ceschi
Journal:  Br J Clin Pharmacol       Date:  2020-02-25       Impact factor: 4.335

4.  "Brief" Aripiprazole-induced Neuroleptic Malignant Syndrome with Symptoms that Only Lasted a Few Hours.

Authors:  Naoto Mizumura; Masato Uematsu; Aya Ito; Satoshi Okumura; Hiromitsu Maehira; Masao Ogawa; Masayasu Kawasaki
Journal:  Intern Med       Date:  2017-09-25       Impact factor: 1.271

5.  Determinants Of Antipsychotic Drugs Prescription Among Community-Living Older Adults With Dementia: A Population-Based Study Using Health Information Systems In The Lazio Region, Italy.

Authors:  Anna Maria Bargagli; Silvia Cascini; Nera Agabiti; Ursula Kirchmayer; Claudia Marino; Marina Davoli
Journal:  Clin Interv Aging       Date:  2019-11-21       Impact factor: 4.458

6.  A bitter pill to swallow - Polypharmacy and psychotropic treatment in people with advanced dementia.

Authors:  Lina Riedl; Esther Kiesel; Julia Hartmann; Julia Fischer; Carola Roßmeier; Bernhard Haller; Victoria Kehl; Josef Priller; Monika Trojan; Janine Diehl-Schmid
Journal:  BMC Geriatr       Date:  2022-03-16       Impact factor: 3.921

7.  Correlates of Opioid Use Among Ontario Long-Term Care Residents and Variation by Pain Frequency and Intensity: A Cross-sectional Analysis.

Authors:  Anita Iacono; Michael A Campitelli; Susan E Bronskill; David B Hogan; Andrea Iaboni; Laura C Maclagan; Tara Gomes; Mina Tadrous; Charity Evans; Andrea Gruneir; Qi Guan; Thomas Hadjistavropoulos; Cecilia Cotton; Sudeep S Gill; Dallas P Seitz; Joanne Ho; Colleen J Maxwell
Journal:  Drugs Aging       Date:  2022-08-17       Impact factor: 4.271

Review 8.  Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review.

Authors:  Marco Solmi; Andrea Murru; Isabella Pacchiarotti; Juan Undurraga; Nicola Veronese; Michele Fornaro; Brendon Stubbs; Francesco Monaco; Eduard Vieta; Mary V Seeman; Christoph U Correll; André F Carvalho
Journal:  Ther Clin Risk Manag       Date:  2017-06-29       Impact factor: 2.423

Review 9.  Potential Anti-COVID-19 Therapeutics that Block the Early Stage of the Viral Life Cycle: Structures, Mechanisms, and Clinical Trials.

Authors:  Rami A Al-Horani; Srabani Kar; Kholoud F Aliter
Journal:  Int J Mol Sci       Date:  2020-07-23       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.